Cytotherapy

Journal Title：Cytotherapy

The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.

該期刊為讀者帶來快速發(fā)展的人類細胞治療領域的最新進展。這包括癌癥、免疫疾病、遺傳疾病、組織修復和再生醫(yī)學的細胞治療。該期刊涵蓋各種細胞類型的科學、轉化發(fā)展和治療，包括造血干細胞、免疫細胞（樹突狀細胞、NK 細胞、T 細胞、抗原呈遞細胞）、間充質基質細胞、脂肪細胞、神經、肌肉、血管和內皮細胞以及誘導性多能干細胞。我們也歡迎有關亞細胞衍生物（如外泌體）的手稿。特別關注將細胞療法帶入臨床的轉化研究。Cytotherapy 發(fā)表原創(chuàng)論文、評論、立場文件社論、評論和致編輯的信。我們歡迎“細胞治療協(xié)議”，為讀者提供用于臨床生產特定細胞類型的標準操作程序。

Cytotherapy創(chuàng)刊于1999年，由Elsevier Inc.出版商出版，收稿方向涵蓋醫(yī)學 - 生物工程與應用微生物全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 偏慢,4-8周 ，影響因子指數3.7，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。